Abstract
RNA aptamers are non-coding small RNAs that bind to their cognate targets with high specificity and affinity. They are generally identified by iterative rounds of in vitro selection termed SELEX (Systemic Evolution of Ligands by Exponential Enrichment). Similar to antibodies, they can inhibit, modulate and disrupt the functions of target proteins effectively, making them promising therapeutic agents for the treatment of various diseases and targeted drug delivery. Herein we summarize the recent progress of RNA aptamers as potential therapeutics, and highlight a few pioneer examples in the stage of both clinical trials and pre-clinical developments.
Keywords: RNA aptamers, SELEX, RNA interference, targeted delivery, therapeutics, diseases.
Current Medicinal Chemistry
Title:Development of RNA Aptamer-Based Therapeutic Agents
Volume: 20 Issue: 29
Author(s): Y. Li, H. Wu, Y. Niu, Y. Hu, Q. Li, C. Cao and J. Cai
Affiliation:
Keywords: RNA aptamers, SELEX, RNA interference, targeted delivery, therapeutics, diseases.
Abstract: RNA aptamers are non-coding small RNAs that bind to their cognate targets with high specificity and affinity. They are generally identified by iterative rounds of in vitro selection termed SELEX (Systemic Evolution of Ligands by Exponential Enrichment). Similar to antibodies, they can inhibit, modulate and disrupt the functions of target proteins effectively, making them promising therapeutic agents for the treatment of various diseases and targeted drug delivery. Herein we summarize the recent progress of RNA aptamers as potential therapeutics, and highlight a few pioneer examples in the stage of both clinical trials and pre-clinical developments.
Export Options
About this article
Cite this article as:
Li Y., Wu H., Niu Y., Hu Y., Li Q., Cao C. and Cai J., Development of RNA Aptamer-Based Therapeutic Agents, Current Medicinal Chemistry 2013; 20 (29) . https://dx.doi.org/10.2174/0929867311320290011
DOI https://dx.doi.org/10.2174/0929867311320290011 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Current Medicinal Chemistry Prospective for Diagnosis and Treatment of Diabetic Retinopathy
Current Pharmaceutical Design Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Purinergic Signalling and Endothelium
Current Vascular Pharmacology Fluocinolone Acetonide Implantable Device for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science CB-12181, a New Azasugar-Based Matrix Metalloproteinase/Tumor Necrosis Factor-α Converting Enzyme Inhibitor, Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and Retinal Neovascularization in Vivo
Current Neurovascular Research Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design